| Course | NR 565 Advanced Pharmacology Fundamentals |
|---|---|
| Week | 8 |
| Paper type | Prescribing rationale |
| Length | About 1,120 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, nurse practitioner core |
| Updated | October 2026 |
Free sample paper for NR 565 Week 8
Prescribing Rationale: Ranking Four Problems for a 76-Year-Old With New Atrial Fibrillation, Stage 3b Kidney Disease, COPD and a Fixed Income, and Why Apixaban 5 mg Twice Daily Wins
Student Name
College of Nursing, Chamberlain University
NR 565: Advanced Pharmacology Fundamentals
Instructor Name
Month Day, Year
Prescribing Rationale: Ranking Four Problems for a 76-Year-Old With New Atrial Fibrillation, Stage 3b Kidney Disease, COPD and a Fixed Income, and Why Apixaban 5 mg Twice Daily Wins
The Patient
A composite 76-year-old patient, a retired church secretary who lives alone in a small town, is seen in a rural clinic two weeks after an emergency visit where new atrial fibrillation was found on an electrocardiogram. The patient was rate-controlled with metoprolol and discharged with a referral. History includes hypertension, chronic kidney disease stage 3b, chronic obstructive pulmonary disease and osteoporosis. Weight is 68 kg, serum creatinine 1.4 mg/dL, estimated creatinine clearance about 40 mL/min and hemoglobin 12.6 g/dL. Current medicines are metoprolol succinate 50 mg daily, lisinopril 20 mg daily, a tiotropium inhaler, albuterol as needed, alendronate 70 mg weekly and calcium with vitamin D. The patient's Medicare Part D plan has a deductible, and the patient has said that some medicines were left unfilled last year because of cost.
Rank the Problems First
Four problems compete for attention: stroke prevention in atrial fibrillation, blood pressure, COPD control and osteoporosis. This rationale treats stroke prevention first. The CHA2DS2-VASc score is 4 (age 75 or older counts two points, female sex one, hypertension one), which places the patient at substantial annual stroke risk, and guidance recommends oral anticoagulation at this score (Joglar et al., 2024). Blood pressure is near goal at 132/80 on current medicines, COPD is stable without exacerbations in the past year, and osteoporosis treatment is established. Those three are reviewed but not changed today. The rest of this document is about one decision.
The Order in Full
Apixaban 5 mg by mouth twice daily, morning and evening, with or without food. Continue metoprolol, lisinopril, inhalers, alendronate, calcium and vitamin D unchanged.
The labeled reduction to 2.5 mg twice daily requires any two of the following: an age of 80 years or more, body weight no greater than 60 kg, or a serum creatinine reaching 1.5. At 76 years, 68 kg and a creatinine of 1.4, this patient has none of them, so the full dose applies. Underdosing apixaban in patients who do not meet these criteria is a common error and leaves the patient less protected. Against warfarin in a large randomized comparison, apixaban produced fewer strokes and embolic events, less major bleeding and lower all-cause death (Granger et al., 2011).
Three Losses, Three Reasons
Warfarin loses on schedule and travel. It is inexpensive and would be the cheapest option in drug cost. But it needs INR monitoring, weekly at first and then about monthly, and the nearest laboratory is 25 miles away; the patient no longer drives at night and depends on a neighbor for rides. Its interactions with antibiotics, which the patient receives for COPD exacerbations, would add further visits. The burden of monitoring is a reason the patient might stop taking it, which would remove the protection altogether.
Dabigatran loses on kidney function. It is about 80% cleared by the kidneys, so a creatinine clearance of 40 mL/min increases exposure and bleeding risk, and dyspepsia is common. Apixaban depends much less on renal clearance, which matters in stage 3b disease.
Rivaroxaban loses on administration and kidney-adjusted dosing. Its kidney-adjusted dose here would be 15 mg a day, and that tablet is absorbed properly only when swallowed with a substantial meal, usually supper. The patient often skips supper and eats a large lunch, which makes a food-dependent evening dose unreliable. Once-daily dosing is convenient, but in this patient the food requirement is the problem.
Bleeding Risk Considered
The HAS-BLED score (Pisters et al., 2010) is 2 (age over 65 and abnormal kidney function), which is not a reason to withhold anticoagulation but flags modifiable factors. The patient takes no aspirin or nonsteroidal anti-inflammatory drugs, drinks alcohol rarely and has controlled blood pressure. The patient is told to avoid over-the-counter ibuprofen and naproxen and to use acetaminophen for pain.
The Problems Not Treated Today
Ranking does not mean ignoring. Blood pressure stays on lisinopril and metoprolol, and lisinopril continues to protect the kidneys; the next visit rechecks potassium and creatinine. COPD control is reviewed at each visit, and the patient is reminded that if an exacerbation needs antibiotics, the prescriber should know about apixaban, although interactions with common respiratory antibiotics are less of a concern than with warfarin. Osteoporosis treatment continues; alendronate is acceptable at this creatinine clearance, but if kidney function falls below about 35 mL/min the bisphosphonate will be reconsidered. Metoprolol's dose will be reviewed once the cardiology referral confirms the rate-control strategy. These items are named here, briefly and on purpose, so that the decision to treat stroke prevention first is clearly a choice of order, not an omission.
Price Treated as Clinical
Apixaban is the most expensive of the options for many Medicare beneficiaries before the deductible is met. Cost is clinical here, because an unfilled prescription protects nobody. The plan: the clinic's pharmacy technician checks the Part D tier and the patient's eligibility for the Extra Help program, applies for the manufacturer's assistance program if eligible, and provides a 30-day starter supply while that is pending. If apixaban remains unaffordable after those steps, warfarin with point-of-care INR testing at the clinic, coordinated with the patient's monthly visits, becomes the named substitute, accepting the monitoring burden as the price of protection.
Follow-Up With Actions Attached
Serum creatinine and hemoglobin at one month and then every six months; if creatinine rises to 1.5 mg/dL or higher and the patient turns 80, the dose falls to 2.5 mg twice daily. A telephone check at one week confirms the prescription was filled and the patient is taking both daily doses. A visit at one month asks about bleeding, bruising, dark stools and adherence. If hemoglobin falls by 2 g/dL or more, the patient is assessed for bleeding, including a stool test and a review of any new medicines from other prescribers, such as a pain reliever bought at the store.
Counseling
The patient hears: this medicine lowers your risk of stroke from your irregular heartbeat; take one tablet every morning and one every evening, about 12 hours apart; do not stop without talking to us, because stopping raises your stroke risk; tell every dentist and doctor you take it; use acetaminophen, not ibuprofen; and call us for black stools, blood in your urine or a fall where you hit your head.
References
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., . . . Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. https://doi.org/10.1056/NEJMoa1107039
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., . . . Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1-e156. https://doi.org/10.1161/CIR.0000000000001193
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest, 138(5), 1093-1100. https://doi.org/10.1378/chest.10-0134
What the NR 565 Week 8 assignment asks for
The final prescribing rationale usually presents a patient with several problems and asks you to choose, justify and monitor one key therapy. Expect the prompt to ask for prioritization, the medication decision, alternatives, follow-up, counseling and cost. Start by ranking the problems and stating which one you treat first and why. Write the prescription in full, checking any dose-adjustment criteria against the patient's age, weight and kidney function. Reject each alternative for a different reason. Address bleeding or other risks with modifiable factors. Treat cost as a clinical variable and name a substitute if the first choice is unaffordable. Set follow-up with tests, intervals and the result that would change the plan. Counsel in patient language.
Inside the NR 565 Week 8 example
The sample introduces the patient two weeks after an emergency visit for new atrial fibrillation, with weight, creatinine, clearance, hemoglobin, current medicines and a history of unfilled prescriptions. It ranks four problems and explains why stroke prevention goes first. The order for apixaban follows, with a check showing the patient meets none of the dose-reduction criteria and a summary of the trial comparing it with warfarin. Three rejected agents each fall on a different ground. A bleeding section reports the HAS-BLED score and removes over-the-counter anti-inflammatories. Another section names the problems left unchanged today. The price section sets out Extra Help, manufacturer assistance and warfarin with clinic INR testing as the substitute, followed by dated follow-up and counseling.
Reading the NR 565 Week 8 grading rubric
Final rationales are typically assessed on ranking, a complete and correctly adjusted prescription, alternatives rejected for different reasons, follow-up with actions and cost handled as part of care. Breadth without ranking loses the most, so this sample names stroke prevention as the first problem and argues one decision. Checking the apixaban dose-reduction criteria against the patient's actual values shows care with the most common dosing error. Three rejections resting on schedule, renal clearance and food dependence show a considered field. Bleeding risk addressed through modifiable factors is a mark of mature prescribing. A named substitute if the drug is unaffordable shows that price was treated as clinical. Follow-up with thresholds and counseling in plain words complete the paper.
NR 565 Week 8 help from the desk
The heaviest loss in the final paper is treating every problem at equal depth, so no decision is argued well. Another is dismissing three alternatives on the same ground, usually side effects, which shows one objection rather than a field. Many papers list tests without intervals or without saying which result would change anything. Some write a dose that ignores the kidney function described earlier, or reduce a dose when the criteria are not met. Price is often mentioned once with no substitute. Rank the problems, check every dosing criterion, give each rival a different reason and name what you would prescribe if cost blocks the first choice. If your final case is different, share it, and a rationale can be built on your patient.
Get a NR 565 Week 8 example written to your instructions
Send the Week 8 case, the rubric and any word limit your section set, and a complete example rationale is written to them and returned inside 24 to 48 hours, the first at no cost. It comes ranked, dosed and defended, with the losing agents argued out one at a time.
More NR 565 papers and MSN samples
- NR 565 Week 1: Pharmacokinetics Discussion Post
- NR 565 Week 2: Thiazide Drug Class Write-Up
- NR 565 Week 3: Pneumonia Prescribing Rationale
- NR 565 Week 4: Pregnancy Hypertension Case Analysis
- NR 565 Week 5: Sample Paper, in Real Form
- NR 565 Week 6: Patient Education Handout
- NR 565 Week 7: Polypharmacy Case Analysis
- NR 545 Week 8: Comprehensive Case Paper
- NR 509 Week 8: Reflection
- NR 507 Week 8: Synthesis Paper
NR 565 Week 8 questions, answered
How do I fit everything into the word limit?
Rank, then cut the background. Most final papers lose a third of their length restating a vignette the instructor wrote and another slice on mechanism that changes nothing. Treat one problem properly, say in a sentence why the others wait, and put the recovered words into the comparative paragraphs and the follow-up plan, which is where the rubric concentrates its points.
Should the three rejected agents be from different classes?
Not necessarily, but their reasons for losing should differ. Two agents from a single class can both be excluded honestly if one fails on elimination and the other on price or schedule. What weakens a paper is three dismissals resting on one objection, because that shows a single consideration applied repeatedly rather than a field of options weighed against a particular patient.
How much detail does the follow-up plan need?
Enough that somebody else could run it. A test, when it happens, which result would prompt a change, and what that change would be. Wording such as monitor regularly is what most submissions offer and it cannot be graded, because no reader can tell whether the writer knows what is being watched for or how fast the drug should work.
Where can I find a free NR 565 Week 8 sample paper?
The apixaban rationale above, which ranks four problems and rejects three rival anticoagulants for different reasons, is the full NR 565 Week 8 sample. A rationale on your own final case can be drafted on request.
How should cost appear in the NR 565 Week 8 rationale?
As a clinical factor with an action attached: check coverage and assistance programs, give a starter supply if possible and name the substitute you would use if the drug stays unaffordable.